Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Severe gastrointestinal disease such as gastroparesis or inflammatory bowel disease can be worsened by the slowed stomach emptying these drugs cause
Cheng H, Zhang Z, Zhang B, Zhang W, Wang J, Ni W, et al
It is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) not yet approved by the MHRA for use in the UK as of mid-2025
January 2011
NVO: The Market Leaders There are currently two major players with a decisive head start in the obesity drug space: Eli Lilly (LLY) and Novo Nordisk (NVO)
US$ 26.65
US$ 25.30
US$ 23.44
US$ 28.07
US$ 27.27
US$ 28.32
US$ 21.33
US$ 27.59
US$ 20.98
